High-Dose Vitamin C for Hemolytic Anemia

(G6PDA PKD Trial)

This trial explores the safety of high-dose Vitamin C for individuals with two rare blood disorders: Pyruvate Kinase Deficiency (PKD) and Class A G6PD Deficiency. These conditions cause rapid red blood cell breakdown, leading to anemia. The study will test various doses and frequencies of Vitamin C to determine the most effective regimen. It is suitable for adults who can take oral medication and have a confirmed diagnosis of one of these disorders. As a Phase 1 trial, the research focuses on understanding the treatment's effects in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team to get a clear answer.

Research has shown that taking high doses of Vitamin C is usually safe, but some issues, such as the breakdown of red blood cells, have been reported. In one study, about 78.6% of participants experienced problems within three days of starting high-dose Vitamin C, though only one death occurred. This indicates that while Vitamin C is generally safe, risks exist, particularly for certain individuals.

Some studies have found that people with G6PD deficiency, a condition that can cause red blood cells to break down, might face more problems with high doses of Vitamin C. However, Vitamin C is primarily known for its ability to combat oxidative stress, which is linked to anemia.

Researchers are excited about high-dose Vitamin C for hemolytic anemia because it explores a new potential treatment avenue for this condition. Unlike the standard treatments, which often include corticosteroids or immunosuppressants that target the immune system, Vitamin C works by potentially stabilizing red blood cells and reducing oxidative stress. The study investigates varying doses, providing insight into how different levels might optimize patient benefits. This approach could offer a more natural and possibly side-effect-free alternative to traditional medications.

Research has shown that Vitamin C might help reduce the breakdown of red blood cells, a major issue in conditions like Pyruvate Kinase Deficiency (PKD) and Glucose-6-Phosphate Dehydrogenase Deficiency (G6PDA). This trial will evaluate different dosages of Vitamin C, with participants receiving either a low dose (250 mg), medium dose (500 mg), or high dose (750 mg) regimen. A previous study found that these doses of Vitamin C reduced red blood cell breakdown by about 50% within an hour. Vitamin C acts as an antioxidant, protecting the body's cells from damage. For people with anemia, this protection might help prevent red blood cells from breaking down too quickly. Although high doses of Vitamin C are generally safe, reports have noted complications like hemolysis (red blood cell breakdown) in some cases, especially for those with G6PDA. This suggests that while Vitamin C shows promise, caution is needed, particularly for people with specific conditions like G6PDA.⁶⁷⁸⁹¹⁰